Cargando…

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Fifteen post-menopausal patients with advanced breast cancer were treated with the LH-RH agonist leuprorelin (D-leu6-des-gly10-Gn-RH-ethylamide) given in a dosage of 7.5 mg as a monthly subcutaneous depot injection, to assess the clinical activity and endocrine response to treatment. None of the 15...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crighton, I. L., Dowsett, M., Lal, A., Man, A., Smith, I. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247121/ https://www.ncbi.nlm.nih.gov/pubmed/2508735

Ejemplares similares

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
por: Plowman, P. N., et al.
Publicado: (1986)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
por: Langley, Ruth E., et al.
Publicado: (2016)

Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report
por: Chang, John I-Chiang, et al.
Publicado: (2016)

Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats
por: He, Wen, et al.
Publicado: (2017)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.
por: Bokser, L., et al.
Publicado: (1990)

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
por: Langley, Ruth E, et al.
Publicado: (2013)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Measuring luteinising hormone pulsatility with a robotic aptamer-enabled electrochemical reader
por: Liang, Shaolin, et al.
Publicado: (2019)

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
por: Ezcurra, Diego, et al.
Publicado: (2014)

Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature
por: Benabbad, Imane, et al.
Publicado: (2018)

Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
por: Secreto, G., et al.
Publicado: (1983)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

Luteinising hormone-based protocol versus traditional flexible gonadotropin-releasing hormone antagonist protocol in women with normal ovarian response: study protocol for a non-inferiority trial
por: Lv, Ya-su, et al.
Publicado: (2021)

Sex Hormone Dependency of Diethylnitrosamine‐induced Liver Tumors in Mice and Chemoprevention by Leuprorelin
por: Nakatani, Tamaki, et al.
Publicado: (2001)

Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial
por: Wang, Yun, et al.
Publicado: (2018)

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
por: Millward, M. J., et al.
Publicado: (1991)

Emirati Women’s Knowledge about the Menopause and Menopausal Hormone Therapy
por: Smail, Linda, et al.
Publicado: (2020)

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey.
por: Thomas, H. V., et al.
Publicado: (1997)

Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin
por: Requena, Antonio, et al.
Publicado: (2014)

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

Advances in hormone replacement therapy: making the menopause manageable
por: Palacios, Santiago
Publicado: (2008)

Field study assessing the performance of a patient-side blood test to determine neuter status in female cats based on detection of luteinising hormone
por: Morrow, Lisa D, et al.
Publicado: (2018)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Hormones and dementia – a comparative study of hormonal impairment in post-menopausal women, with and without dementia
por: Robusto-Leitao, Olívia, et al.
Publicado: (2006)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Progestogens in menopausal hormone therapy
por: Bińkowska, Małgorzata, et al.
Publicado: (2015)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Effect of insulin-like growth factor system on luteinising angiogenesis
por: Nwachukwu, Chinwe U, et al.
Publicado: (2023)

A Comparison of Outcomes from In Vitro Fertilization Cycles Stimulated with Follicle Stimulating Hormone Plus either Recombinant Luteinizing Hormone or Human Menopausal Gonadotropins in Subjects Treated with Long Gonadotropin Releasing Hormone Agonist Protocols
por: Bleau, Nathalie, et al.
Publicado: (2017)

Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study
por: Moradan, Sanam
Publicado: (2018)

Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.
por: Hargreaves, D. F., et al.
Publicado: (1998)

Bioidentical Hormones for Menopausal Hormone Therapy: Variation on a Theme
por: Fugh-Berman, Adriane, et al.
Publicado: (2007)

Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy
por: Thounaojam, Menaka C., et al.
Publicado: (2017)

Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice
por: Ren, Hao-Lin, et al.
Publicado: (2023)

Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice
por: Boido, Marina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5hjubbsds4h4gfpsjns949fi3